Quick answer: A sample should not be approved only because it holds the target volume and looks correct. Before commercial filling, the veterinary product developer should confirm the final component configuration, the amount actually expelled, line-handling suitability, batch consistency and the packaging system used for stability work.

Moving an empty intramammary syringe from an initial sample to commercial production is a scale-up exercise. The decisive question is not whether one sample works once, but whether the same packaging configuration can be filled, assembled, transported and dispensed consistently across production batches.

This article focuses on production qualification rather than basic syringe selection or formulation viscosity. It is intended for veterinary pharmaceutical companies, animal health brands and contract fillers preparing to move from pilot filling to bulk supply.

Why Packaging Qualification Matters for Intramammary Products

EMA guidance on the development of veterinary medicinal products states that primary packaging should be justified with attention to the manufacturing method, container integrity and potential product-container interaction. The same guidance makes a particularly relevant point for unit-dose intramammary products: the amount expelled should be considered rather than relying only on the fill weight.

VICH stability guidance also expects the medicinal product to be studied in the container-closure system proposed for marketing. These requirements apply to the medicinal product developer and its regulatory program, not to an empty-packaging supplier by itself. However, they explain why the final syringe, cap, plunger, tip and secondary packaging configuration should be fixed before formal stability and commercial scale-up work begins.

1. Lock the Final Component Configuration

Sample approval should identify the exact bill of materials rather than only the nominal syringe size. Record the barrel reference, plunger, cap, applicator-tip configuration, color, printing area and component-supply format. A change to any of these items may affect assembly, sealing, dispensing or line handling.

2. Measure the Quantity Actually Expelled

Nominal capacity and target fill quantity are important, but they do not show how much product leaves the syringe. Residual material can remain on the barrel wall, plunger face or within the outlet. The buyer should therefore define a repeatable method for measuring the delivered or expelled quantity under controlled conditions.

The objective is not to create a universal acceptance limit for every formulation. It is to establish product-specific evidence that the selected unit-dose package delivers a consistent amount throughout the expected operating range.

3. Reproduce the Actual Filling and Assembly Sequence

Bench filling can hide problems that appear on a production line. Pilot work should reproduce the intended component orientation, filling direction, plunger insertion, cap placement, inspection and packing sequence as closely as possible.

For a compact reference, buyers can review the 5ml intramammary syringe. Projects requiring a larger reference can compare the 13ml intramammary syringe. The two sizes have different dimensions, so each selected configuration should be assessed on its own production setup rather than assumed to behave identically.

4. Set Batch-Consistency Checks Before the First Bulk Order

A successful sample is only the starting point. Before scale-up, the buyer and supplier should agree which incoming checks are critical for repeatability. These may include dimensional checks, visual inspection, component fit, plunger travel, cap retention, print position and packaging count. Acceptance criteria should be linked to the final approved configuration and the buyer’s filling process.

5. Test the Filled System After Packing and Transport Simulation

The syringe is part of a complete packaging system. Filled samples should be assessed after the intended packing method and suitable distribution simulation. The review may include component movement, cap displacement, visible leakage, deformation, print damage and dispensing after storage. Formal validation remains the responsibility of the veterinary product developer, but early transport screening can identify obvious risks before commercial launch.

6. Create Clear Change-Control Triggers

Requalification should be considered when a change could affect the filled product or manufacturing process. Typical triggers include a different barrel reference, cap or tip design, plunger material or geometry, filling direction, printing process, component packaging method, production line or formulation. The scope of retesting should be determined by the product developer according to risk and regulatory requirements.

A Practical Scale-Up Checklist

✓ Is the tested sample identical to the proposed commercial component set?

✓ Has expelled quantity been evaluated, not only the amount filled?

✓ Has the actual filling and assembly sequence been reproduced?

✓ Are incoming batch checks and acceptance criteria documented?

✓ Has the filled and packed system been reviewed after transport simulation?

✓ Are supplier and process changes linked to a defined requalification decision?

Xinfuda Empty Intramammary Syringe References

Xinfuda supplies empty PE intramammary syringe packaging references in 5ml, 8ml, 10ml and 13ml capacities. The products are supplied as empty packaging components and do not contain veterinary medicine or active pharmaceutical ingredients. Component configuration, printing and packaging requirements can be discussed according to the project.

Final suitability must be established by the veterinary pharmaceutical company or its contract filling partner through formulation-specific filling, delivery, stability, transport and regulatory evaluation.

Frequently Asked Questions

What is the most common scale-up mistake?

Approving a single sample without fixing the complete component configuration and production presentation. A barrel, plunger, cap or tip change can create a different packaging system.

Should fill quantity or expelled quantity be checked?

Both are useful, but for a unit-dose intramammary product the amount actually expelled is especially important because it reflects what the delivery system releases.

Can one qualification result cover every syringe size?

Not automatically. Different sizes have different dimensions and may interact differently with the filling line, packing method and product.

When should the packaging supplier be involved?

Ideally before pilot filling, so the component set, supply format, samples and bulk-production expectations can be aligned early.

Plan the Next Filling Trial

To prepare a useful packaging discussion, provide the target fill quantity, selected syringe size, final component configuration, filling sequence, sample quantity and expected annual demand. Discuss your empty intramammary syringe filling project with Xinfuda.

Industry References

• EMA - Note for Guidance on Development Pharmaceutics for Veterinary Medicinal Products

• EMA - Plastic Primary Packaging Materials: Scientific Guideline

• VICH GL3 - Stability Testing of New Veterinary Drug Substances and Medicinal Products